Clene Past Earnings Performance
Past criteria checks 0/6
Clene's earnings have been declining at an average annual rate of -15.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 25.4% per year.
Key information
-15.5%
Earnings growth rate
20.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 25.4% |
| Return on equity | n/a |
| Net Margin | -8,556.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Clene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -36 | 14 | 21 |
| 30 Jun 24 | 0 | -30 | 14 | 23 |
| 31 Mar 24 | 1 | -49 | 14 | 25 |
| 31 Dec 23 | 1 | -50 | 14 | 27 |
| 30 Sep 23 | 1 | -40 | 15 | 28 |
| 30 Jun 23 | 1 | -49 | 15 | 28 |
| 31 Mar 23 | 1 | -28 | 16 | 31 |
| 31 Dec 22 | 0 | -30 | 17 | 32 |
| 30 Sep 22 | 0 | -24 | 18 | 34 |
| 30 Jun 22 | 0 | 15 | 19 | 33 |
| 31 Mar 22 | 1 | 17 | 21 | 31 |
| 31 Dec 21 | 1 | -10 | 22 | 28 |
| 30 Sep 21 | 1 | -13 | 18 | 23 |
| 30 Jun 21 | 1 | -53 | 16 | 21 |
| 31 Mar 21 | 0 | -55 | 10 | 18 |
| 31 Dec 20 | 0 | -19 | 5 | 15 |
| 30 Sep 20 | 0 | -24 | 5 | 14 |
| 30 Jun 20 | 0 | -19 | 6 | 12 |
| 31 Mar 20 | 0 | -16 | 6 | 11 |
| 31 Dec 19 | 0 | -16 | 7 | 10 |
Quality Earnings: 84C0 is currently unprofitable.
Growing Profit Margin: 84C0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 84C0 is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare 84C0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 84C0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 84C0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.